India, June 24 -- Eli Lilly and Company (LLY) announced Wednesday the completion of its acquisition of Centessa Pharmaceuticals plc, a clinical-stage company developing orexin receptor 2 agonists for the treatment of narcolepsy and other sleep-wake disorders.
The acquisition was intended to expand Lilly's neuroscience portfolio into sleep medicine.
"The orexin system plays a fundamental role in human brain health, governing wakefulness, alertness, and the stability of sleep in ways that, when disrupted, can be profoundly disabling," said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience.
Centessa Pharma's lead drug investigational candidate Cleminorexton (formerly ORX750) is in Phase 2a clinical studies across n...